Key Developments: Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

115.40EUR
11:35am EST
Price Change (% chg)

€1.40 (+1.23%)
Prev Close
€115.00
Open
€114.35
Day's High
€116.60
Day's Low
€114.30
Volume
1,841,643
Avg. Vol
2,392,171
52-wk High
€121.40
52-wk Low
€91.31

Search Stocks

Latest Key Developments (Source: Significant Developments)

Bayer AG to divest equine assets to Merial, Inc.
Tuesday, 16 Dec 2014 07:00pm EST 

Bayer AG:Enters into a definitive agreement to sell its equine products Legend/Hyonate (hyaluronate sodium) and Marquis (ponazuril) to Merial, Inc.The deal is expected to close in the first quarter 2015 subject to customary conditions, including relevant merger control clearance.  Full Article

Bayer and DNDi sign human river blindness treatment agreement
Tuesday, 9 Dec 2014 07:40am EST 

Bayer AG:Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness.  Full Article

Bayer AG completes acquisition of Dihon Pharmaceutical in China
Sunday, 2 Nov 2014 07:00pm EST 

Bayer AG:Has completed acquisition of 100 pct of shares of Dihon Pharmaceutical Group Co., Ltd., Kunming, Yunnan, China.Says Bayer paid purchase price of CNY 3.6 billion (approx. 460 million euros).  Full Article

Bayer AG successfully places $7 billion jumbo bond
Thursday, 2 Oct 2014 02:00am EDT 

Bayer AG:Places jumbo bond with volume of $7 billion.Net cash provided by bond will replace part of bridge financing secured in connection with takeover of Merck & Co's OTC unit.  Full Article

Merck & Co Inc completes sale of consumer care business to Bayer AG for $14.2 bln
Wednesday, 1 Oct 2014 11:30am EDT 

Merck & Co Inc:Completes previously announced sale of the Merck Consumer Care (MCC) business to Bayer AG.Effective Oct. 01, Bayer will acquire Merck's existing over-the-counter business, including the global trademark and prescription rights for CLARITIN and AFRIN, for $14.2 bln or about $9 bln.  Full Article

Bayer AG subsidiary Cropscience to buy seed business of Granar S.A.
Wednesday, 1 Oct 2014 09:00am EDT 

Bayer AG:Says subsidiary Bayer Cropscience announced today that it has entered into an agreement to purchase seed business of Granar S.A.Will start selling Igra Semillas brand from 2015.  Full Article

Bayer AG receives approval for EYLEA for the treatment of myopic choroidal neovascularization in Japan
Monday, 22 Sep 2014 02:30am EDT 

Bayer AG:Says has received approval for EYLEA for treatment of myopic choroidal neovascularization from the Ministry of Health, Labour and Welfare in Japan.  Full Article

Bayer AG plans to float MaterialScience business
Thursday, 18 Sep 2014 02:52am EDT 

Bayer AG:Plans to focus group entirely on Life Science businesses - HealthCare and CropScience - and float MaterialScience on stock market as separate company.  Full Article

Bayer and Orion initiate phase III trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer
Tuesday, 16 Sep 2014 02:30am EDT 

Orion Corp and Bayer HealthCare:Begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development.Study, called ARAMIS, evaluates ODM-201 in men with castration-resistant prostate cancer who have rising Prostate Specific Antigen (PSA) levels and no detectable metastases.Trial is designed to determine the effects of the treatment on metastasis-free survival.  Full Article

Bayer and Orion initiate phase III trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer
Tuesday, 16 Sep 2014 02:30am EDT 

Bayer AG:Says together with Orion Corporation initiates phase III trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer.  Full Article

UPDATE 2-China officially approves imports of Bayer GMO soy variety

(Adds comments from Bayer's director of U.S. soybean operations)

Search Stocks